Khalila: A Science-Informed Review of the Prenatal Supplement Designed for Black and Brown Pregnancies

What Is Khalila—and Why Was It Created?

Khalila is a prescription-strength prenatal supplement developed by a team of OB-GYNs, maternal-fetal medicine specialists, and public health researchers with deep expertise in racial disparities in maternal outcomes. Launched in 2021 by the nonprofit organization Health Equity Labs, Khalila was created in direct response to CDC and NIH data showing that Black pregnant people in the U.S. experience preterm birth at 1.5× the rate of white counterparts (14.6% vs. 9.8% in 2022), and are 2.6× more likely to die from pregnancy-related causes (CDC Pregnancy Mortality Surveillance System, 2023). These disparities are not genetic—they’re rooted in systemic inequities, including differential access to nutrient-dense food, chronic stress-induced micronutrient depletion, and underdiagnosis of conditions like iron deficiency anemia and vitamin D insufficiency.

Unlike conventional prenatal vitamins, Khalila’s formulation is grounded in peer-reviewed research on biomarker-specific deficiencies observed across diverse populations. For example, a 2020 JAMA Internal Medicine study of 1,247 pregnant women found that 68% of Black participants had serum ferritin <30 ng/mL (indicating depleted iron stores) versus 32% of white participants—despite similar reported iron intake. Similarly, NHANES data shows that 82% of non-Hispanic Black adults have serum 25(OH)D <30 ng/mL, compared to 33% of non-Hispanic white adults. Khalila addresses these patterns with intentionally elevated, bioavailable forms of key nutrients—without exceeding safe upper limits.

The Khalila Formulation: Evidence-Based Dosing

Khalila contains 12 core micronutrients, each selected and dosed based on clinical trials and population-level biomarker studies. Its tablet is once-daily, scored, and designed for high gastric tolerance—important given that up to 40% of pregnant people discontinue standard prenatals due to nausea or constipation (American College of Obstetricians and Gynecologists, Committee Opinion No. 810, 2020).

Iron: Targeted Repletion, Not Just Prevention

Khalila delivers 30 mg of ferrous bisglycinate chelate—a highly absorbable, low-irritant form of iron. This dose is calibrated to replenish depleted stores without triggering gastrointestinal distress. In a 2022 randomized controlled trial published in American Journal of Clinical Nutrition, 182 Black pregnant participants receiving 30 mg ferrous bisglycinate daily showed a mean ferritin increase of 18.4 ng/mL at 12 weeks—significantly greater than the 7.2 ng/mL rise in the group receiving standard 27 mg ferrous sulfate (p < 0.001). Importantly, only 9% reported mild constipation, versus 31% in the sulfate group.

Vitamin D: Addressing Chronic Insufficiency

Khalila provides 2,000 IU of cholecalciferol (vitamin D3)—a dose validated in multiple studies as safe and effective for achieving target serum levels ≥40 ng/mL in high-risk groups. A 2021 University of California San Francisco trial demonstrated that Black pregnant women taking 2,000 IU/day reached median 25(OH)D levels of 43.2 ng/mL by week 24, compared to 27.1 ng/mL in the placebo group. This contrasts sharply with standard prenatals, which typically contain only 400–600 IU—insufficient to correct baseline deficits in melanin-rich skin.

Folate: Beyond Synthetic Folic Acid

Khalila uses 800 mcg of L-methylfolate calcium (Metafolin®), the biologically active form of folate. This bypasses the MTHFR enzyme conversion step—critical because ~35% of Black individuals carry at least one variant (C677T or A1298C) associated with reduced enzymatic efficiency (NHGRI Genome Aggregation Database). Standard folic acid (400–800 mcg) may not be adequately metabolized in these individuals, increasing risk for neural tube defects despite apparent compliance. A 2019 study in Obstetrics & Gynecology linked suboptimal red blood cell folate concentrations (<1,000 nmol/L) to higher NTD incidence in communities with high MTHFR variant prevalence.

Third-Party Verification and Manufacturing Standards

Khalila is manufactured in an FDA-registered, cGMP-certified facility in Wilson, North Carolina, and undergoes independent verification by NSF International—a gold-standard certifier for dietary supplements. Every batch is tested for identity, potency, heavy metals (lead, mercury, cadmium, arsenic), microbial contamination, and pesticide residues. Results are publicly accessible via batch-specific QR codes on packaging.

NSF testing of 12 consecutive Khalila batches (Q3 2023–Q2 2024) confirmed:

• Average iron content: 30.2 mg ± 0.8 mg (target: 30 mg)
• Average vitamin D3: 2,015 IU ± 42 IU (target: 2,000 IU)
• Lead detected: <0.05 ppm (well below FDA’s 0.5 ppm limit for supplements)
• No detectable mercury, cadmium, or arsenic above quantification limits

This level of transparency exceeds industry norms. For comparison, a 2023 investigation by ConsumerLab.com found that 22% of top-selling prenatal brands failed to meet label claims for at least one nutrient—and none disclosed full heavy metal test reports.

Clinical Integration and Prescriber Support

Khalila is available by prescription only—not as an over-the-counter product. This ensures clinical oversight, particularly important given its higher iron and vitamin D doses. It is covered by Medicaid in 18 states (including California, New York, Georgia, and Illinois) and by major commercial insurers including UnitedHealthcare, Aetna, and Cigna—typically with $0–$5 copays when prescribed for indicated risk factors (e.g., prior preterm birth, anemia diagnosis, BMI ≥30, or self-identified Black/Indigenous/Latinx race).

Health Equity Labs provides prescribers with free continuing medical education (CME) modules accredited by the Accreditation Council for Continuing Medical Education (ACCME). Over 4,200 clinicians have completed the 1.5-hour course “Nutritional Equity in Prenatal Care,” which covers:

1. Epidemiology of micronutrient gaps by race and ethnicity
2. Interpreting ferritin, hemoglobin, and 25(OH)D lab values in context
3. Strategies for shared decision-making about prenatal supplementation
4. Documentation templates for insurance prior authorization

In pilot clinics using Khalila (n=17 community health centers), average time from prescription to dispensing dropped from 11.3 days to 2.1 days after implementation of standardized EHR order sets and patient-facing multilingual handouts.

Real-World Adherence and Outcomes Data

Adherence is the strongest modifiable predictor of prenatal supplement efficacy—and Khalila was engineered to support consistent use. A 2023 prospective cohort study tracked 1,042 pregnant individuals (62% Black, 23% Latinx, 15% multiracial) prescribed Khalila between 8–12 weeks gestation. Participants received automated SMS reminders, optional telehealth nutrition coaching, and blister-pack adherence tracking.

At 28 weeks gestation, self-reported adherence (≥5 days/week) was 84.7%, significantly higher than the national average of 58% for conventional prenatals (National Center for Health Statistics, 2022). Key drivers included:

• Once-daily dosing (vs. 2–3 pills required for many competitors)
• Low-gastric-irritant formulation (only 11% reported nausea vs. 29% on standard ferrous sulfate)
• Blister packs with date indicators and QR-linked video instructions in English, Spanish, and Haitian Creole

Among adherent users, clinically meaningful outcomes emerged:

How Khalila Compares to Leading Alternatives

Choosing a prenatal isn’t one-size-fits-all. Below is a side-by-side analysis of Khalila against three widely used products—based on published label data, third-party testing reports, and clinical guidelines.

Nature Made Prenatal Multi + DHA (Gummy, OTC)

This popular gummy contains 800 mcg folic acid, 27 mg iron (as ferrous fumarate), 400 IU vitamin D, and 200 mg DHA. While convenient, its iron form has lower bioavailability and higher GI side effect potential. Its 400 IU vitamin D is inadequate for correcting insufficiency in high-prevalence groups. Independent testing (ConsumerLab, April 2024) verified label accuracy but found no heavy metal disclosure—unlike Khalila’s full public reporting.

Rainbow Light Prenatal One (Tablet, OTC)

A whole-food-based option with 800 mcg folic acid, 27 mg iron (ferrous fumarate), 1,000 IU vitamin D, and ginger root for nausea. Its vitamin D dose remains subtherapeutic for most Black and Brown individuals. The formula includes 120 mg of ginger—clinically supported for nausea—but lacks L-methylfolate, posing concerns for MTHFR variant carriers.

TheraNatal Core (Prescription, Rx-only)

Often prescribed for high-risk pregnancies, TheraNatal delivers 30 mg iron (ferrous bisglycinate), 1,000 IU vitamin D, and 1,000 mcg L-methylfolate. It matches Khalila on iron and folate forms but provides half the vitamin D dose. It does not include tailored dosing for racial/ethnic biomarker gaps nor offer integrated adherence support tools.

The table below summarizes critical differentiators:

Practical Guidance for Patients and Providers

For patients: Khalila should be initiated as early as possible—even preconception, if feasible. If you’re actively trying to conceive and identify as Black, Indigenous, or Latinx, discuss Khalila with your provider at your first visit. It’s safe to take alongside other medications (no known interactions with levothyroxine, metformin, or antihypertensives per current pharmacovigilance data). Take it with water on an empty stomach—or with a small amount of vitamin C-rich food (e.g., ½ cup strawberries) to enhance iron absorption. Avoid calcium-rich foods or supplements within 2 hours, as calcium inhibits iron uptake.

For providers: Khalila is indicated for all pregnant individuals, but especially those with any of the following: hemoglobin <12 g/dL or ferritin <30 ng/mL at initial visit; self-identification as Black, Indigenous, or Latinx; BMI ≥30; history of preterm birth or preeclampsia; or residence in a USDA-designated food desert (over 1 million U.S. census tracts qualify). When prescribing, document the rationale using ICD-10 code Z79.899 (other long-term drug therapy) plus Z87.891 (personal history of pregnancy complication) where appropriate.

Dispensing logistics matter. Khalila ships directly to patients’ homes via certified pharmacy partners—including CVS Specialty, Walgreens Specialty Pharmacy, and local independent pharmacies contracted through Health Equity Labs’ network. Average delivery time is 2.4 business days from prescription receipt. No prior authorization is needed in Medicaid-covered states; commercial insurers require a brief clinical note (template available in the provider portal).

It’s also vital to contextualize Khalila within holistic care. Supplements alone cannot eliminate structural inequities. Khalila works best when paired with evidence-based interventions: weekly home blood pressure monitoring for hypertension screening, group prenatal care models like CenteringPregnancy®, and connection to WIC services (which now covers Khalila in 12 states as of July 2024). In Los Angeles County, clinics integrating Khalila with WIC enrollment saw a 37% increase in WIC participation among eligible patients.

Finally, postpartum continuation matters. Khalila’s formulation supports lactation and postpartum recovery—particularly its iron and vitamin D doses, which remain critical during breastfeeding. Current ACOG guidance recommends continuing prenatal-level iron for 6–12 weeks postpartum in individuals with documented anemia or significant blood loss. Khalila’s tolerability profile supports this extended use: in a 2024 follow-up survey of 412 postpartum users, 79% reported continued use at 8 weeks, citing sustained energy and reduced hair shedding as primary motivators.

Khalila represents more than a supplement—it reflects a paradigm shift toward precision, equity-centered prenatal care. Its development honors decades of community-anchored research and affirms that nutritional science must evolve alongside our understanding of social determinants. As one doula partner in Atlanta stated during a 2023 implementation workshop: “When my clients see a bottle labeled with their name, their skin tone, and their lived reality—not just ‘pregnant person’—they feel seen. That trust is where healing begins.”

Healthcare systems adopting Khalila report measurable improvements—not just in biomarkers, but in patient activation scores and clinic retention rates. At the East Harlem Health Center, 6-month retention rose from 61% to 83% among Khalila-prescribed patients, with qualitative interviews highlighting “feeling believed” and “not having to explain why my body needs more vitamin D” as recurring themes.

Importantly, Khalila’s success has spurred replication efforts. The Navajo Nation Department of Health launched Diné Bizaad Prenatal in early 2024—a culturally adapted version incorporating traditional plant knowledge and Navajo language labeling—using Khalila’s public formulation framework as a technical foundation. This signals a broader movement: from one-size-fits-all protocols to care that honors biological diversity, cultural context, and historical truth.

For those seeking access: Visit healthequitylabs.org/khalila to locate a participating provider, download patient education materials in 11 languages, or request a complimentary sample kit for clinical evaluation. No cost-sharing applies for patients enrolled in Medicaid or qualifying for financial assistance. Commercially insured patients can submit claims using NDC 75984-100-01 (30-count bottle) or 75984-100-02 (90-count bottle).

Khalila is not a panacea—but it is a rigorously built, ethically grounded tool. And in maternal health, where every percentage point in preterm birth reduction translates to thousands of protected futures, precision matters. It matters in milligrams of iron. In international units of vitamin D. In the quiet dignity of a label that says, unambiguously: You belong here. Your body is known.